Activation of cytotoxic T lymphocytes by self-differentiated myeloid-derived dendritic cells for killing breast cancer cells expressing folate receptor alpha protein
Issued Date
2022-01-01
Resource Type
ISSN
21655979
eISSN
21655987
Scopus ID
2-s2.0-85132606183
Pubmed ID
35734827
Journal Title
Bioengineered
Volume
13
Issue
6
Start Page
14188
End Page
14203
Rights Holder(s)
SCOPUS
Bibliographic Citation
Bioengineered Vol.13 No.6 (2022) , 14188-14203
Suggested Citation
Luangwattananun P., Chiraphapphaiboon W., Thuwajit C., Junking M., Yenchitsomanus P.T. Activation of cytotoxic T lymphocytes by self-differentiated myeloid-derived dendritic cells for killing breast cancer cells expressing folate receptor alpha protein. Bioengineered Vol.13 No.6 (2022) , 14188-14203. 14203. doi:10.1080/21655979.2022.2084262 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/83899
Title
Activation of cytotoxic T lymphocytes by self-differentiated myeloid-derived dendritic cells for killing breast cancer cells expressing folate receptor alpha protein
Author's Affiliation
Other Contributor(s)
Abstract
Adoptive cell transfer (ACT) is a promising approach for cancer treatment. Activation of T lymphocytes by self-differentiated myeloid-derived antigen-presenting-cells reactive against tumor (SmartDC) resulted in specific anti-cancer function. Folate receptor alpha (FRα) is highly expressed in breast cancer (BC) cells and thus potential to be a target antigen for ACT. To explore the SmartDC technology for treatment of BC, we create SmartDC expressing FRα antigen (SmartDC-FRα) for activation of FRα-specific T lymphocytes. Human primary monocytes were transduced with lentiviruses containing tri-cistronic complementary DNA sequences encoding granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-4 (IL-4), and FRα to generate SmartDC-FRα. Autologous T lymphocytes were activated by SmartDC-FRα by coculture. The activated T lymphocytes exhibited enhanced cytotoxicity against FRα-expressing BC cell cultures. Up to 84.9 ± 6.2% of MDA-MB-231 and 89.7 ± 1.9% of MCF-7 BC cell lines were specifically lysed at an effector-to-target ratio of 20:1. The cytotoxicity of T lymphocytes activated by SmartDC-FRα was also demonstrated in three-dimensional (3D) spheroid culture of FRα-expressing BC cells marked by size reduction and spheroid disruption. This study thus portray the potential development of T lymphocytes activated by SmartDC-FRα as ACT in FRα-expressing BC treatment.